Ann: FDA Grants PharmAust Pre-IND Meeting, page-38

Hi Tym1ng,

You may have nailed the timing here.

PharmAust has had some special results in clinical and Human (Cancer) trials in the past with MPL.

Have look back at the Phase 1 Human Trial in Cancer and Pre-Clinical Trials of MPL in Cancer and Covid, or viruses in general. They are, to quote the Head of Epidemiology at Walter and Eliza Hall Institute Prof Marc Pellegrini, “remarkable”.

Our former CEO resigned on the 27th May 2022, and the first MND trial patient was dosed 3rd October 2022.

The MEND trials first cohort completion was announced on the 6th January 2023 and shortly after that, from the 6-9th January 2023, Director SW bought 165 thousand shares on market. An interim analysis of the MND trial was recommended on the 2nd March 2023 and Director SW bought another 185 thousand shares on the market on the 10th March 2023.

On the 28th of March 2023 it was announced that“After six months on MPL, a Cohort 1 patient in the MND trial remains stable”and on the 13th April PharmAust announced they had commenced a search for a new CEO.

On the 23rd May PharmAust announced that the Olivia Newton John Cancer Research Institute had found “Monepantel has anti-cancer effects across multiple cancer types”. Here is how Cancer Cell Viability is affected:

Note the effect on brain cancers and given MPL seems to be able to cross the Blood-Brain barrier it could be promising in brain cancers.

On the 4th July 2023 PharmAust announced the MND biomarker and Pharmacodynamics results for Cohort 1, the lowest dose at 2mg/kg.

On the 11th July PharmAust announce further cohort 1 results.

On the 13th December PharmAust announced that Merchant Biotech Fund had approached PharmAust to become a strategic investor in PharmAust. MBF has become a top 5 shareholder.

Anecdotal evidence suggests things are progressing well and I will be interested to see results from the remaining 3 higher dose cohorts.

However, there are no sure things in life, except the usual culprits. If things don’t work out, it’s back to curing COVID and the next major virus that comes out or cancer. That might be worth something???

It is great to see the staff that have been employed to progress this. New CEO, new staff in manufacturing, trialling, marketing and corporate advisory. I don’t think the new boss necessarily expects to be around too long in the job given the big pharma appetite for drugs with ODD and treating neurological disorders. We have plenty of cash in the bank so a clear runway for share price appreciation following results and ODD approval. 93% of Option holders renewed their Reward Options which have since 5 bagged.

Good luck with your own research.

Regards,

Havelots

Not long now…

Sorry about the repost. Pictures didn’t load properly again.